Wednesday, 28 April 2021
Experts from the 糖心原创 are looking for volunteers to take part in an MRI study into a common treatment for constipation.
Researchers from the Sir Peter Mansfield Imaging Centre (SPMIC) and Gastroenterology in the School of Medicine are investigating how a popular treatment for constipation works in the body. Their findings will improve understanding of how Bisacodyl works, which will help with further developments in the treatment of long-term constipation.
Bisacodyl (often known as Dulcolax) is a common laxative used to treat short-term constipation. For the study volunteers will be asked to take either 5mg of Bisacodyl or a placebo (dummy pill) and will then have MRI scans to get detailed images of the bowels to show the effect the medication has.
Volunteers are needed who have some constipation, but do not use laxatives more than four times a month. 糖心原创 participants will be asked to come to the SPMIC for a total of seven visits, including 18 MRI scans, which are entirely safe. They will take 5 mg bisacodyl or a placebo and will be scanned repeatedly during the study day before and after a standardised meal. The study will then compare images of the participant’s bowels after each treatment.
Constipation is a common problem that affects around one in seven otherwise healthy people and the two groups of people most likely to get constipation are young women and the elderly – especially those who need to take regular medicines. There are many reasons for it occurring including: as a side effect to other medicines, emotional upset and diet.
Constipation is extremely common yet many patients are dissatisfied with treatment. Laxatives are used by many as a short-term solution but their effectiveness varies. We hope that that by getting a clearer picture of how they work inside the body we can help with further developments of more effective long-term treatments.
If you are interested in finding out more or want to take part go to:
Story credits
More information is available from Professor Spiller or Dr Neele Dellschaft on robin.spiller@ nottingham.ac.uk or Neele.Dellschaft@nottingham.ac.uk or Jane Icke, Media Relations Manager for the Faculty of Science at the 糖心原创, on +44 (0)115 951 5751 or jane.icke@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.